$BIAF News

BioAffinity Technologies Announces 200% Sales Growth YoY For CyPath Lung Cancer Diagnostic

bioAffinity To Present Preclinical Findings For Therapeutic Approach That Uses siRNAs That Kill Squamous And Basal Skin Cancer Cells In Vitro At 2026 RNA Therapeutics Symposium

bioAffinity Technologies Prices $3.2M Offering Of 4M Shares (Or Pre-funded Warrants) At $0.80/Share ($0.793/Warrant)

bioAffinity Receives Mexican Institute Of Industrial Property Allowance For A Patent Application Regarding Methods Of Predicting The Likelihood Of Lung Cancer Using Flow Cytometry

BioAffinity Technologies Reports April CyPath Lung Diagnostic Unit Sales Up 300% YoY

bioAffinity Technologies Reports Record Monthly Unit Sales Of CyPath Lung Diagnostic Tests, 300% Increase In Sales YoY

bioAffinity Technologies Q1 EPS $(0.81) Beats $(2.70) Estimate, Sales $1.352M Miss $1.553M Estimate

bioAffinity Technologies shares are trading higher after the company announced a pilot study evaluating its tests for chronic obstructive pulmonary disease in collaboration with Brooke Army Medical Center.

bioAffinity Partners With U.S. Military Medical Center To Develop AI-Driven Diagnostics For Asthma And COPD

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16

bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

bioAffinity Technologies shares are trading higher after the company announced a year-over-year increase in its Q1 CyPath Lung Diagnostic unit sales.

bioAffinity Technologies Reports Q1 CyPath Lung Diagnostic Unit Sales Up 146% YoY

bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

What's Going On With bioAffinity Technologies Stock Wednesday?

What's Going On With bioAffinity Stock Thursday?

New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

Why Is bioAffinity Technologies Stock Surging Tuesday?

bioAffinity Technologies shares are trading higher after the company announced a new clinical case study that highlights the benefit of adding CyPath Lung, a noninvasive test for lung cancer, to the diagnostic pathway for a high-risk patient with multiple pulmonary nodules.

bioAffinity Technologies Releases New Clinical Case Study Highlighting Benefit Of Adding CyPath Lung To Diagnostic Pathway For High-Risk Patient With Multiple Pulmonary Nodules